CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
XS Muscle Multiplierdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05117112
NCT05117112N/ACompleted

Nutritional Biomarkers of Sarcopenia

University of Arkansas·interventional·Posted Nov 11, 2021·Updated Sep 25, 2024

In Brief

A clinical study evaluating XS Muscle Multiplier for Sarcopenia. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This study proposes to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), in order to determine the state of muscle health. Analogous to the oral glucose tolerance test (OGTT) used to characterize alterations in glucose metabolism, the proposed OATT represents a potential low-cost solution to classifying patients' skeletal muscle health. The extrapolation of this work is the development of a simple analytical tool that would provide clinicians the ability to discern alterations in muscle amino acid kinetics prior to a loss of function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 11, 2021
Enrollment StartApr 8, 2022
Primary CompletionJan 12, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.6 years ago

Interventions

XS Muscle Multiplierdietary

Distributed by Amway; this product is a powder, sold in a 6.8 ounce (192g) container.